Vol 16, No 3 (2023)
Case report
Published online: 2023-06-26
Acquired haemophilia A treated with recombinant factor VIIa by an infusion pump and midline catheter - case study
1, 2
, 23
, 23
DOI: 10.5603/jtm.94832
Journal of Transfusion Medicine 2023;16(3):141-145.
Abstract
Acquired haemophilia A is an autoimmune bleeding disorder treated with immunosuppression and bypassing agents such as recombinant factor VIIa (rFVIIa). The half time of rFVIIa is short, which requires frequent bolus injections in order to maintain hemostasis. Providing a continuous pump infusion instead of bolus injections could not only be more time and cost-efficient but also safer by maintaining a constant level of the bypassing agent.
rFVIIa is administered intravenously usually through a peripheral venous catheter. In patients with prolonged intravenous treatment or difficult-to-access peripheral vasculature, midline long peripheral intravenous catheters are an interesting alternative. They have favourable dwell times and failure rates while maintaining the same risk of infection as other peripherally inserted central catheters. This technique has potential to reduce the costs as well as risk to the patients.
Herein, we report patient with AHA, who was treated with rFVIIa by an infusion pump and midline catheter.
Keywords: acquired haemophilia Ainfusion pumprecombinant factor VIIamidline catheter
References
- Webert KE. Acquired hemophilia A. Semin Thromb Hemost. 2012; 38(7): 735–741.
- Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015; 21(2): 162–170.
- Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7): 1791–1801.
- Bonde C, Jensen MB. Continuous infusion of recombinant activated factor VII: stability in infusion pump systems. Blood Coagul Fibrinolysis. 1998; 9 Suppl 1: S103–S105.
- Négrier C, Chamouard V, Lienhart A, et al. A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system. Haemophilia. 2019; 25(6): 1020–1027.
- Pollard D, Subel B, Chowdary P, et al. Use of an innovative syringe pump to deliver bolus rFVIIa for patients with haemophilia and inhibitors undergoing surgery. J Haem Pract. 2018; 4(1): 35–39.
- Bing S, Smotherman C, Rodriguez RG, et al. PICC versus midlines: Comparison of peripherally inserted central catheters and midline catheters with respect to incidence of thromboembolic and infectious complications. Am J Surg. 2022; 223(5): 983–987.
- Moulin V, Monti M. [Central venous catheter, PICC-line or Midline : which catheter for my patient?]. Rev Med Suisse. 2022; 18(766): 121–125.
- Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother. 2002; 36(5): 882–891.
- Tarantino MD, Cuker A, Hardesty B, et al. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017; 23(1): 25–32.
- Rexen P, Jensen JT, Schwerin NB, et al. Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump. TH Open. 2019; 3(1): e45–e49.
- Lu H, Hou Y, Chen J, et al. Risk of catheter-related bloodstream infection associated with midline catheters compared with peripherally inserted central catheters: A meta-analysis. Nurs Open. 2021; 8(3): 1292–1300.
- Adams DZ, Little A, Vinsant C, et al. The Midline Catheter: A Clinical Review. J Emerg Med. 2016; 51(3): 252–258.
- Tripathi, S., Kumar, S., & Kaushik, S. The Practice and Complications of Midline Catheters: A Systematic Review. Crit Care Med. 2021; 49(2): e140–e150.
